Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Current UrologyOpen Access

Clinical evaluation of combined programmed cell death protein 1 inhibitor and poly(ADP-ribose) polymerase inhibitor in metastatic castration-resistant prostate cancer patients: Insights from a real-world study

View Full Paper
Ask AI
Bookmark
Share

Authors

YSYuan ShaoZLZihao LiuYZYinchi Zhang

Discussion

Loading...

Member takes

Overview

Real-world study shows combination therapy improves radiographic progression-free survival in mCRPC patients, suggesting potential biomarkers.

Key Points

  • The combination therapy demonstrates a median overall survival of 8.1 months in patients with metastatic castration-resistant prostate cancer.
  • Exploratory analysis identified pretreatment prostate-specific antigen levels as prognostic biomarkers for treatment outcomes.
  • Treatment-related adverse events were reported by 87.5% of participants, indicating a need for careful safety monitoring.
  • The study provides insights from a real-world perspective, enhancing understanding of treatment effectiveness in clinical practice.

Cite This Study

Shao et al. (2025) studied this question.

synapsesocial.com/papers/68c23bd7b210217d64786eedhttps://doi.org/10.1097/cu9.0000000000000304
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1PARP Inhibitors for Metastatic CRPC: More Answers than Questions, a Systematic Review and Meta-Analysis.2025
  2. 2Efficacy and safety of first-line treatments for metastatic castration-resistant prostate cancer based on phase II and III randomized controlled trials: A PROSTA-MAP systematic review and network meta-analysis2025
  3. 3Exploring the efficacy of PARP inhibitors in metastatic castration-resistant prostate cancer with homologous recombination repair alteration: a meta-analysis based on subgroups and reconstructed individual patient data2025 · 3 citations
  4. 4Assessing the clinical outcomes of immunotherapy and docetaxel combinations in metastatic castration-resistant prostate cancer: a meta-analysis2025
  5. 5Adding programmed death 1/programmed death ligand 1 inhibitors to first-line standard-of-care therapy for metastatic colorectal cancer: A meta-analysis2025